How can Germany succeed in mobilising more private capital for the life sciences? Can a new public fund that invests with private investors set a new standard for financing life sciences companies? What are the options? An interview with Michael Kring, High Tech Services GmbH, Dr Siegfried Bialojan (formerly of EY), Dr Claus Kremoser, WMT AG, and Andreas Huber, Bayern Kapital GmbH.
Read more in this article published in Plattform Life Sciences - Finanzieren & Investieren
DSD Bio RN LS 2-2022
.pdf
Download PDF • 7.16MB